Equity Overview
Price & Market Data
Price: $0.175
Daily Change: -$0.005 / 2.86%
Daily Range: $0.164 - $0.208
Market Cap: $3,471,567
Daily Volume: 1,102,952
Performance Metrics
1 Week: -5.67%
1 Month: -33.61%
3 Months: -40.88%
6 Months: -44.77%
1 Year: -70.54%
YTD: -60.54%
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis that is in Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.